Dean L. Schorno

2020 - Rigel Pharmaceuticals

In 2020, Dean L. Schorno earned a total compensation of $1.2M as Executive Vice President and Chief Financial Officer at Rigel Pharmaceuticals, a 16% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$155,952
Option Awards$613,158
Salary$424,360
Other$9,054
Total$1,202,524

Schorno received $613.2K in option awards, accounting for 51% of the total pay in 2020.

Schorno also received $156K in non-equity incentive plan, $424.4K in salary and $9.1K in other compensation.

Rankings

In 2020, Dean L. Schorno's compensation ranked 7,825th out of 13,090 executives tracked by ExecPay. In other words, Schorno earned more than 40.2% of executives.

ClassificationRankingPercentile
All
7,825
out of 13,090
40th
Division
Manufacturing
3,306
out of 5,621
41st
Major group
Chemicals And Allied Products
1,341
out of 2,254
41st
Industry group
Drugs
1,164
out of 1,954
40th
Industry
Pharmaceutical Preparations
868
out of 1,459
41st
Source: SEC filing on April 6, 2021.

Schorno's colleagues

We found four more compensation records of executives who worked with Dean L. Schorno at Rigel Pharmaceuticals in 2020.

2020

Raul Rodriguez

Rigel Pharmaceuticals

Chief Executive Officer

2020

Dolly Vance

Rigel Pharmaceuticals

Executive Vice President, Corporate Affairs, General

2020

David Santos

Rigel Pharmaceuticals

Executive Vice President and Chief Commercial Officer

2020

Wolfgang Dummer

Rigel Pharmaceuticals

Chief Medical Officer

News

In-depth

You may also like